New to the Huntington's Disease Lighthouse?
 Welcome to the HDlighthouse!
 Getting started.
 
Home \ Research \ Drugssupps \ Updates
  HD Lighthouse Editor's Comment: AEOL 10150 is moving from the lab to the clinic. This antioxidant molecule passes the blood brain barrier and is anti-inflammatory.

An antioxidant that reduces stroke damage is relevant to Huntington's disease because both conditions have reduced blood flow. --Jerry

Posted to HDLighthouse: 01-Oct-2002 12:42 GMT
HDL Update: Antioxidant Reduces Brain Damage in Stroke Model


A Better Antioxidant
"Our findings suggest that the antioxidant is a promising candidate for stroke therapy because it can prevent damage so many hours after the stroke begins.", said researcher James Crapo, M.D.

New research shows that a synthetic antioxidant can reduce brain damage by more than 40 percent in an animal model of stroke when given seven and a half hours after the stroke begins. Researchers at National Jewish Medical and Research Center and Duke University Medical Center will report their findings in the October issue of the journal Free Radical Biology and Medicine.

"Because the onset of a stroke can be difficult to detect, many patients do not get treatment for several hours," said James Crapo, M.D., co-author and Chairman of the Department of Medicine at National Jewish.

Strokes occur when blood supply to the brain is interrupted because blood vessels in the brain either leak or are blocked. Starved of oxygen, the brain cells die. However, cell death continues to occur for many hours, even after blood flow is returned to the brain. Many of the cells that are injured, but not killed by oxygen deprivation, die in the hours following the stroke. Free radicals, highly reactive molecules, kill many of those cells.

The researchers used a synthetic antioxidant, known as AEOL 10150, to neutralize the damaging free radicals and reduce cell death in a mouse model of stroke. AEOL 10150, developed by Dr. Crapo and his colleagues at Duke, mimics the naturally occurring antioxidant superoxide dismutase, but is effective against a wider range of oxygen radicals and lasts longer in the body. Now licensed by Incara Pharmaceuticals Corporation, it has shown promise in preventing damage to cells caused by diabetes and radiation therapy for cancer.

The researchers blocked the middle cerebral artery of rats for 90 minutes. They then injected AEOL 10150 or a placebo into the brains of these mice six hours after the artery had been reopened. The six-hour post-stroke time period has significant clinical relevance. In an unrelated stroke study, 26 percent of patients received treatment within four hours, but 99 percent received treatment within six hours.

When evaluated a week later, animals who received the placebo had an average of 160 cubic millimeters of brain tissue destroyed by the stroke. Animals who received the antioxidant had an average of 92 cubic millimeters of brain tissue destroyed by the stroke, 43 percent less than that the rats who received the placebo.

"There is a significant arc of potentially salvageable tissue surrounding the cells that are killed by the initial stroke," said David S. Warner, M.D., professor of anesthesiology at Duke University Medical Center. "The antioxidant appears to protect this tissue."

The researchers also treated mice with intravenous injections of the antioxidant. Although, this method produced a smaller effect, it reduced both tissue damage and neurological deficit, demonstrating the compound's ability to cross the blood-brain barrier. Mechanistic studies also showed that the antioxidant significantly altered inflammatory gene expression in tissue.

# # #

Source: National Jewish Medical and Research Center --01-Oct-2002
Read the HDAC/HDLighthouse Forum. Post your comments
   

 

Vitamin E caution
A new analysis of data from past studies shows that high doses of Vitamin E are associated with higher rates ...
Marsha L. Miller, Ph.D.
Posted to HDL: 12 Nov 2004

Herb used in Chinese medicine has potential as a treatment for neurodegenerative disorders
Celastrol, derived from an herb used in traditional Chinese medicine for many years, shows promised as a treatment for HD. ...
Marsha L. Miller, Ph.D.
Posted to HDL: 05 Nov 2004

Neither aspirin nor Vioxx help the HD mice
Neither aspirin nor Vioxx, drugs selected for their anti-inflammatory properties, help either of two models of HD mice, a new ...
Marsha L. Miller, Ph.D.
Posted to HDL: 30 Oct 2004

HDAC inhibitor is neuroprotective in HD mice
Phenylbutyrate, a histone deacetylase (HDAC) inhibitor, has been shown to be neuroprotective in a mouse model of HD. ...
Marsha L. Miller, Ph.D.
Posted to HDL: 26 Oct 2004

Minocycline neuroprotection in Huntington's Disease

LaVonne Veatch Goodman, M.D.
Posted to HDL: 17 Oct 2004

Throughput Assays Identify New Candidates for Treatment

We have developed a medium-throughput cell-based assay to screen drugs for Huntington\'s disease (HD). The assay measures the ability of ...
Marsha L. Miller, Ph.D.
Posted to HDL: 10 Sep 2004

Two Phase II Studies of Minocycline are now complete
Two Phase II trials with minocycline have ended and both found minocycline to be safe and tolerated by Huntington\'s Disease ...
Marsha L. Miller, Ph.D.
Posted to HDL: 22 Aug 2004

Low side effects found with elderly dementia patients taking Seroquel
Recently we noted the lack of clinical trials for medications to treat HD symptoms. Neuroleptics or antipsychotic drugs are ...
Marsha L. Miller, Ph.D.
Posted to HDL: 06 Aug 2004

Dr. David Rubinsztein

Marsha L. Miller, Ph.D.
Posted to HDL: 30 Jul 2004

Geldanamycin arrests neurodegeneration in a fruitfly model
Scientists have found a way of successfully treating flies that were given human degenerative brain diseases. ...
Marsha L. Miller, Ph.D.
Posted to HDL: 22 Jul 2004
[an error occurred while processing this directive]

Disclaimer & Privacy Policy | Welcome | Site Feedback Marsha@HDLighthouse.org